Payden Equity Income Fund Adviser Cl
PYVAX · NASDAQ
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
|---|---|---|---|---|
| Revenue | $9 | $10 | $11 | $12 |
| % Growth | -12.3% | -0.3% | -9.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $9 | $10 | $11 | $12 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $7 | $8 | $8 | $7 |
| SG&A Expenses | $7 | $8 | $8 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $102 | $112 | $132 | $55 |
| Operating Income | $2 | $3 | $3 | $5 |
| % Margin | 23.8% | 27.3% | 27.8% | 43.2% |
| Other Income/Exp. Net | $109 | -$104 | $139 | $62 |
| Pre-Tax Income | $112 | -$101 | $142 | $67 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $112 | -$101 | $142 | $67 |
| % Margin | 1,213.7% | -967.4% | 1,353.2% | 576.3% |
| EPS | 2.77 | -2.53 | 3.62 | 1.7 |
| % Growth | 209.5% | -169.9% | 112.9% | – |
| EPS Diluted | 2.77 | -2.53 | 3.62 | 1.7 |
| Weighted Avg Shares Out | – | – | – | – |
| Weighted Avg Shares Out Dil | – | – | – | – |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$3 | -$3 | -$5 |
| EBITDA | $109 | -$104 | $139 | $62 |
| % Margin | 1,189.9% | -994.6% | 1,325.4% | 533.1% |